Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 834

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 834
---
 yet released) that became unrestricted in January 2024 and $1,500 of restricted cash related to the New Lease in long-term assets. After the first and second anniversaries of the rent commencement date, the face amount of the letter of credit relating to the New Lease can be reduced by $500 each period if the Company is not in default of its lease obligations. As of December 31, 2022, the Company had $408 of restricted cash related to the Stamford Lease in current assets. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.

| ​                                                                                                    | ​ | ​ | December 31, 2023 |   |        |   | ​ | ​ | December 31, 2022 |   |        |   | ​ |
|:-----------------------------------------------------------------------------------------------------|:--|:--|:------------------|:--|-------:|:--|:--|:--|:------------------|:--|-------:|:--|:--|
| Cash and cash equivalents                                                                            | ​ | ​ | ​                 | $ | 51,775 | ​ | ​ | ​ | ​                 | $ | 63,741 | ​ | ​ |
| Restricted cash, current assets                                                                      | ​ | ​ | ​                 | ​ |    408 | ​ | ​ | ​ | ​                 | ​ |    408 | ​ | ​ |
| Restricted cash, long-term assets                                                                    | ​ | ​ | ​                 | ​ |  1,500 | ​ | ​ | ​ | ​                 | ​ |      — | ​ | ​ |
| Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows | ​ | ​ | ​                 | $ | 53,683 | ​ | ​ | ​ | ​                 | $ | 64,149 | ​ | ​ |

F-59

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data) 9. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ | ​ | December 31, 2023 |   |        |   | ​ | ​ | December 31, 2022 |   |